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Introduction: To evaluate the current utilization and challenges in fully implementing the
use of deep brain stimulation (DBS) treatment in Asia and Oceania.
Methods: We conducted a medical literature search to identify DBS research performed
by investigators with a primary affiliation in Asian and Oceania countries between
March 1, 2013, and March 1, 2019, followed by an international survey-based
study. Additionally, we obtained added information regarding the DBS challenges and
opportunities from the technology/industry perspective within China and Japan. We also
described the current situation of DBS in India.
Results: Most publications (390/494; 78.95%) in the English language originated from
East Asia. In West Asia, Turkey, Israel, and Iran accounted for most DBS publications. We
found no publications from the remaining 35 Asian countries. Lack of community referrals
to tertiary centers was identified as the most common limitation for the widespread use
of DBS in Asia (68.97%). In China, despite an increasing number of centers performing
DBS surgeries, most of them accomplished less than 10 cases per year. In contrast, the
number of DBS cases in Japan has been decreasing. Centers offering DBS surgeries as
well as corresponding fellowship training in India are limited.
Conclusion: Appropriate referrals, access, infrastructure, and the presence of full
multidisciplinary DBS teams are common limitations of DBS in Asia. Most centers in
China, Japan, and India performed less than 10 cases per year and a future study is
expected to address the impact on quality in centers performing such few cases.
Keywords: deep brain stimulation, Asia, Oceania, China, Japan, India
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INTRODUCTION
Deep brain stimulation (DBS) is a safe and effective treatment
for medically refractory brain disorders. DBS was approved by
the United States Food and Drug Administration as a treatment
for essential tremor and Parkinson’s disease (PD) in 1997,
dystonia in 2003, obsessive-compulsive disorder (OCD) in 2009,
and epilepsy in 2018 (Okun, 2014; Li and Cook, 2018). DBS
has been recently studied in small clinical trials as a potential
treatment for other psychiatric disorders, e.g., major depression
(Crowell et al., 2019), addiction (Chen et al., 2019; Zhang
et al., 2019), and Tourette syndrome (Johnson et al., 2019;
Ramirez-Zamora et al., 2019).
Expertise gained from surgical ablation has strongly
influenced the clinical use of DBS, in particular the choice
of targeted brain regions. The well-established long-term
efficacy of bilateral high-frequency stimulation applied to
different brain regions, coupled with the partially reversible
nature of DBS and the possibility of reducing dopaminergic
medications in PD patients has led to the global evolution
toward DBS over ablative procedures to treat motor fluctuations
and complications in PD (Krack et al., 2019). However, even
in PD, less than 2% of eligible patients worldwide undergo
DBS (Chan et al., 2014; Willis et al., 2014; Kestenbaum et al.,
2015; Lee, 2015; Poortvliet et al., 2015; Ezat et al., 2017;
Wagle Shukla et al., 2018).
Barriers to widespread adoption of DBS therapy include
difficulties in predicting response and identifying appropriate
candidates. There has been a reluctance of clinicians to
refer patients for surgery, a shortage of personnel trained
in DBS programming and issues about access to expert
centers. Logistical barriers include expensive procedural costs
and lack of insurance coverage. In many centers, long
waiting lists for DBS surgery and the fear of brain surgery
are common concerns, particularly in developing countries
(Abosch et al., 2013).
A critical aspect of the effectiveness of DBS is patient selection.
Another important aspect related to DBS success is choosing
the appropriate brain target and surgical approach including
factors such as the patient’s symptom profile, age, and cognitive
status (Okun et al., 2004; Moro et al., 2016). These choices
rely heavily on the expertise of the multidisciplinary team
and vary from center to center. Most DBS studies have been
published in European and North American countries (Hu
et al., 2017) and there has been limited information regarding
the local use and challenges of DBS in other world regions.
More than two-thirds of people in the world reside in Asia
and Oceania. To facilitate ongoing communication among these
countries, the First 2019 DBS Think Tank East meeting was
held on June 3rd, 2019 in Kyoto, Japan. A goal of this meeting
was to provide a detailed survey of DBS practices within
Asia and Oceania.
The objective of the international survey was to collect and
share information on the current status of DBS surgery in Asia
and Oceania and to achieve a better understanding of the local
DBS challenges and opportunities. A complete literature review
of DBS cases in Asia and Oceania was performed in addition
to the survey. We present the results of the survey and the
literature review.
MATERIALS AND METHODS
Study Design
We designed this international survey study in March 2018 for
the 2019 DBS Think Tank East meeting, which was held
on June 3rd, 2019 in Kyoto, Japan. A 54-question internet-
based survey was developed (designed with SurveyMonkey1)
to ascertain various aspects of DBS surgical practice in Asian
and Oceania regions including but not limited to: demographic
information, DBS center information, number of different kinds
of DBS surgeries (in 2018), team composition, specific surgical
information, side effects, post-surgery management, number of
patients, number of surgeries, as well as information on cost.
The study conformed to the American Association for Public
Opinion Research (AAPOR) regarding informed consent from
the participants and compliance with human research ethics.
Survey Question Formulation and Survey
Tool
We initially conducted a literature review using the PubMed
database searching for DBS studies published in English
from Asia in the last 5 years at the stage of meeting
preparation (i.e., between March 1, 2013, and March 1,
2018). The period was subsequently extended to March 1,
2019, to include more information before the meeting in
June 2019. The Mesh term (or team) ‘‘DBS’’ was entered
in the ‘‘Title/Abstract’’ field and country name, including
‘‘China,’’ ‘‘Japan,’’ ‘‘Korea,’’ ‘‘Mongolia,’’ etc. in the ‘‘Affiliation’’
field. Full country lists are included in Table 1. Basic
science animal experiments, reviews, and publications using
a language other than English were excluded. Searching
results were manually verified. Only the corresponding author’s
affiliation was used to define the ‘‘nationality’’ of the article.
Subsequently, we contacted all corresponding authors by email
to participate in this survey and to complete the electronic
questionnaire. As stated in the invitation email, completion
of the survey by participants was considered as implied
consent. Responses were collected from May 17th, 2019 to
July 8th, 2019.
Statistical Analysis
The survey results have been summarized descriptively.
Quantitative data are presented as the median and interquartile
range (IQR; 25th–75th percentile) and qualitative data are
presented as ‘‘percentage.’’
RESULTS
DBS Development in Asia and Australia
We identified 494 studies, the majority of which [390/494
(78.95%)] were from East Asia (e.g., China, Japan, South Korea).
Of the 114 centers identified from publications, 73 were in
1https://www.surveymonkey.com/r/eastdbs
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East Asia or Australia. For West Asia, Turkey, Israel, and Iran
contributed to the most publications. There were thirty-five
countries (71%) without any English publications on DBS
according to our searching strategy (Table 1).
TABLE 1 | Publications and deep brain stimulation centers in Asia and Oceania.
No. Country No. of
publicationsa
Publicationsa
per 10 million
person
No. of centers
identified
from
publications
Centers per
10 million
person
Population
(10 million)b
Ratio
publications/
centers
GDP per
capita
(US dollars)c
1 China 210 1.46 23 0.16 143.38 9.13 9,770.85
2 Japan 91 7.17 22 1.73 12.69 4.14 39,286.74
3 Korea d 89 17.37 10 1.95 5.12 8.90 31,362.75
4 Turkey 24 2.88 13 1.56 8.34 1.85 9,311.37
5 Australia 22 8.73 18 7.14 2.52 1.22 57,305.30
6 Iran 19 2.29 10 1.21 8.29 1.90 5,627.75
7 India 16 0.12 6 0.04 136.64 2.67 2,015.59
8 Israel 13 15.29 4 4.71 0.85 3.25 41,614.00
9 New Zealand 1 2.08 2 4.17 0.48 0.50 41,966.01
10 Saudi Arabia 3 0.87 2 0.58 3.43 1.50 23,219.13
11 Singapore 2 3.45 1 1.72 0.58 2.00 64,581.94
12 Philippines 2 0.19 1 0.09 10.81 2.00 3,102.71
13 Malaysia 1 0.31 1 0.31 3.19 1.00 1,1238.96
14 Nepal 1 0.35 1 0.35 2.86 1.00 1,025.80
15 Lebanon 0 0 0 0 0.69 NA 8,269.79
16 Thailand 0 0 0 0 6.96 NA 7,273.56
17 Afghanistan 0 0 0 0 3.80 NA 520.90
18 Armenia 0 0 0 0 0.30 NA 4,212.07
19 Azerbaijan 0 0 0 0 1.00 NA 4,721.18
20 Bahrain 0 0 0 0 0.16 NA 24,050.76
21 Bangladesh 0 0 0 0 16.30 NA 1,698.26
22 Bhutan 0 0 0 0 0.08 NA 3,360.27
23 Brunei 0 0 0 0 0.04 NA 31,627.74
24 Burma 0 0 0 0 5.40 NA 1,325.95
25 Cambodia 0 0 0 0 1.65 NA 1,512.13
26 Cyprus 0 0 0 0 0.12 NA 28,159.30
27 East Timor 0 0 0 0 0.13 NA 2,035.53
28 Georgia 0 0 0 0 0.40 NA 4,344.63
29 Indonesia 0 0 0 0 27.06 NA 3,893.60
30 Iraq 0 0 0 0 3.93 NA 5,878.04
31 Jordan 0 0 0 0 1.01 NA 4,247.77
32 Kazakhstan 0 0 0 0 1.86 NA 9,331.05
33 Kuwait 0 0 0 0 0.42 NA 34,243.95
34 Kyrgyzstan 0 0 0 0 0.64 NA 1,281.36
35 Laos 0 0 0 0 0.72 NA 2,567.54
36 Maldives 0 0 0 0 0.05 NA 10,223.64
37 Mongolia 0 0 0 0 0.32 NA 4,103.70
38 Oman 0 0 0 0 0.50 NA 16,418.93
39 Pakistan 0 0 0 0 21.66 NA 1,472.89
40 Palestine 0 0 0 0 0.50 NA NA
41 Qatar/Katar 0 0 0 0 0.28 NA 69,026.47
42 Sri Lanka 0 0 0 0 2.13 NA 4,102.48
43 Syria 0 0 0 0 1.71 NA 2,032.62
44 Tajikistan 0 0 0 0 0.93 NA 826.62
45 The United Arab
Emirates
0 0 0 0 0.98 NA 43,004.95
46 Turkmenistan 0 0 0 0 0.59 NA 6,966.64
47 Uzbekistan 0 0 0 0 3.30 NA 1,532.37
48 Vietnam 0 0 0 0 9.65 NA 2,563.82
49 Yemen 0 0 0 0 2.92 NA 944.41
aWe searched in Pubmed Database and included hurman studies published in English from Asia Between March 1, 2013, and March 1, 2019. The term “Deep brain stimulation” was
entered in the “Title/Abstract” field and country name, including “China,” “Japan,” “Korea,” etc. in the “Affiliation” field. Basic science animal experiments, reviews, and publications
using a language other than English were excluded. Supplementary information from manufacturers was also used for DBS center identification. bPopulation data is obtained
from World Population Prospects 2019 (total population, both sexes combined, as of 1 July 2019), United Nation (https://population.un.org/wpp/Download/Standard/Population/).
cData is obtained from The World Bank, GDP per capita (most recent year https://data.worldbank.org/indicator/NY.GDP.PCAP.CD). d“Korea” was used for both South Korea and North
Korea. There were no publications from North Korea. Data on the population as well as GDP per capita include only South Korea.
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Experience of Neurologists and
Neurosurgeons
We received 37 answers from 32 DBS centers across nine
countries. Most responses were from East Asia and Australia
[27/37 (73%); Supplementary Table S1]. Most centers
interviewed [31/36 (86%)] were major referral centers in
their respective countries. The median number of DBS surgery
centers interviewed was 14 (IQR 10–18) years (Supplementary
Figure S1A).
Among the 37 respondents, 22 (60%) were neurosurgeons
and 11 (30%) were neurologists. Additionally, two physiologists,
one psychiatrist, and one neuro-engineer participated
(Supplementary Figure S1C). Approximately half [18/37
(49%)] of respondents specialized in functional neurosurgery
and approximately one-quarter [9/37 (24%)] identified as
specialists in movement disorders; the rest practiced in the fields
of neurophysiology, neuropsychiatry, and in general medicine
(Supplementary Figure S1D). The median years of clinical
experience was 13.0 (IQR 8.5–17.0) years, which was similar to
the time engaged in utilizing neuromodulation techniques [14.0
(IQR 8.5–19.5) years; Supplementary Figure S1B]. Despite the
relatively long history of DBS, 10/24 (42%) respondents had
not performed more than 25 surgeries in 2018, and only one
team reported performing more than 200 DBS surgeries in the
previous year (Supplementary Figure S1E).
Management of DBS: Surgical Team
Members, Software and Hardware
Perioperative management of DBS is usually a multidisciplinary
effort that involves neurologists, neurosurgeons, physical
therapists, psychiatrists, psychologists, and case managers. Our
data suggested that in Asia the team usually involves more
neurologists [3 (IQR 2–3.75)] than neurosurgeons [2 (IQR 1–3);
Supplementary Table S2, Supplementary Figure S2A]. The
number of physicians or therapists increased at centers with
larger surgical volumes (Supplementary Table S3).
Most centers [31/33 (94%)] used microelectrode recording
(MER) to identify appropriate brain areas for implantation.
Only one center preferred to implant using intraoperative
magnetic resonance imaging (MRI) or computed tomography
(CT) for lead localization (Supplementary Figure S2B). Leksell
SurgiPlan and Stealth were the two most popular planning
software programs utilized for stereotactic neurosurgery [26/32
(81%); Supplementary Figure S2C]. Approximately 5% (95%
CI 5–10%) of all procedures were reported as unsatisfactory
related to hardware (1.6% of all cases, 95% CI 1–2%) or
surgery-related (1% of all cases, 95% CI 1–2%) complications
(Supplementary Figure S2D). Neurologists were responsible
for postoperative DBS programming in over half of the centers
(21/32 [66%]). Most teams offered DBS programming, DBS
troubleshooting, and non-DBS outpatient movement disorder
evaluations [28/29 (97%), 22/29 (76%), and 23/29 (79%),
respectively]. A large proportion of centers also endorsed
conducting preclinical research [23/29 (80%)]. Nearly half of the
DBS centers [14/29 (48%)] did not provide rehabilitation services
for DBS patients. It was unclear if the teams worked consistently
in a multidisciplinary fashion and how multidisciplinarity
was defined.
Since DBS is a well-established treatment option for PD,
essential tremor (ET), and dystonia, we further investigated
and compared the preferred clinical workflow for these
three disorders. Simultaneous bilateral lead implantation was
predominantly performed for PD [28/29 (97%)], ET [23/29
(79%)], and dystonia [28/29 (97%); Supplementary Figure S2E].
Various DBS devices are available for clinicians and patients
to use. Device reliability was the most important factor in the
decision [23/29 (80%)], followed by customer support [17/29
(59%)] and programming feasibility [16/19 (55%)]. However,
patient preference, as well as insurance coverage (i.e., the
final cost to the patient and other funding considerations),
played a minor role. Unsurprisingly, economic issues affected
DBS centers in developing countries (p = 0.000023). Only
one center in Iran and one in Turkey decided on device
selection based on government-related factors (Supplementary
Table S4). Insurance and government support covered the
expenses for device and hospital services in all of the DBS
centers in developed countries (p = 0.005) making DBS
potentially more accessible to patients in these regions
(Supplementary Table S5). Conversely, in developing
countries, out-of-pocket payment served as the main form of
reimbursement (p = 0.000023).
Major Obstacles for DBS Accessibility and
Development
More than half of responders [16/29 (55%)] indicated that
the main limiting factors for access to surgery included:
(1) insufficient referrals due to limited understanding of DBS
by general medical providers [20/29 (69%)]; (2) fear of brain
surgery by patients [17/29 (59%)]; and (3) high cost of the device
and procedure [12/29 (41%)], with cost issues most notable in
developing countries (p = 0.001; Supplementary Table S6). DBS
is an established treatment for some neurological movement-
related diseases and is a promising investigational approach
for psychiatric disorders (e.g., OCD and depression). Lack of
funding was a major barrier to increasing scientific research. The
survey also uncovered difficulties in recruiting patients and in
publishing results (Supplementary Table S7).
DBS in China and Japan
DBS was introduced in China in 1998 (source of information
Beijing Tiantan Hospital) and has undergone considerable
development in the past 20 years. In the last 3 years, the number
of DBS centers in China has increased, with over 200 DBS leads
implanted per year/center. More than 100 Chinese hospitals
performed less than 10 cases annually (Figure 1A). In contrast,
the number of DBS implantations in Japan has decreased since
2015 (Figure 1B). While 966 cases underwent DBS implantation
in 2015, there were only 761 cases in 2018 (according to
Medtronic Japan). Among the 44 institutions approved as
training centers (≥18 cases/3 years) by the Japanese Society for
Stereotactic and Functional Neurosurgery (JSSFN) in 2019, most
centers performed less than two cases per month. Although
our survey did not investigate factors associated with these
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FIGURE 1 | The number of deep brain stimulation (DBS) implant cases in China (A) and Japan (B). (A) DBS surgery became more popular in China in recent years.
Histogram with different gray bars shows the number of hospitals performing DBS electrode implantation each year on the left Y-axis. The total number of hospitals is
then indicated by the black “•” The total number of implanted leads is shown by the red “•” on the right Y-Axis. (B) Japan performed less DBS surgeries since 2015.
Red “H” shows the total number of DBS implanted cases between 2014 and 2018 in Japan. Black “•,” “,” and “N” indicate each number of DBS implant cases of
three main manufacturers (Abottr, Boston Scientificr, and Medtronic Japanr, respectively) in Japan.
small numbers, possibly, these numbers were influenced by the
introduction of focused ultrasound (FUS) and other advanced
therapies, e.g., levodopa gastrointestinal gel. Since November
2016, when the FUS obtained approval for the treatment of
essential tremor, 210 cases were treated with FUS (November
2016 to October 2019).
DBS in India
The first DBS surgery in India was performed in a private
hospital, Jaslok Hospital and Research Center, by Prof. Paresh
Doshi (Ganapathy, 2013). There has been a steady increase in
interest in DBS over the past 20 years. Currently, 3/4 premier
state-run neuroscience centers perform DBS surgeries regularly,
which include All India Institute of Medical Sciences in
New Delhi, National Institute of Mental and Neurosciences
(NIMHANS) in Bengaluru, and Sree Chitra Tirunal Institute
for Medical Sciences and Technology in Trivandrum. In total,
12 centers offer DBS with at least 10 DBS surgeries occurring
per year, and another 12–15 centers with much fewer numbers
of cases per year. Generally, most provide DBS surgeries for
all movement disorders. Two centers, Jaslok Hospital and
NIMHANS, also perform DBS for psychiatric disorders. The
DBS surgical programs in most hospitals are actively supported
by movement disorder specialists. Though not all surgeons
have formal fellowship training in functional neurosurgery, the
neurologists in most centers have obtained fellowship training
specialized in movement disorders, either in India or overseas.
The movement disorder fellowship is offered in 8–10 centers in
India, whereas Jaslok Hospital provides the unique functional
neurosurgical training. Three societies, the Indian Society for
Stereotactic and Functional Neurosurgery, the Neuromodulation
Society, and the Movement Disorders Society of India, are
involved in DBS in India. Two major companies, Medtronic and
Boston Scientific, provide most of the DBS implants in India.
SceneRay and Abbott are, however, just entering the market.
The use of DBS has increased and though an exact estimate
cannot be made, approximately 450 DBS surgeries/year are being
performed in India.
India has a legacy of lesional surgeries for movement
disorders (Doshi, 2009). Most centers perform such
interventions mainly for unilateral dystonia, including task-
dystonia, and tremors (Doshi et al., 2017). All centers refrain
from offering bilateral lesional surgeries. Compared to developed
nations, the number of patients undergoing lesional surgery (or
DBS) for essential tremors is very low.
Most DBS surgeries are self-funded. However, there is
currently an increasing tendency for insurance reimbursements.
Owing to the social customs of family support in India, many
PD patients are funded by their children who are now earning
adequately. There is also a growing trend towards seeking DBS
for a moderately advanced disease by neurologists and patients
compared to 10 years ago.
DISCUSSION
These data provide a detailed and previously unknown
description of DBS practices and practice patterns in centers
from Asia and Oceania. These data will serve as a reference for
addressing the challenges and limitations of DBS in these regions.
We also hope that through the DBS Think Tank East there will
be dialogue including relevant stakeholders and medical societies
to discuss potential solutions and opportunities to the challenges
uncovered by the survey. Though outcomes including clinical
effectiveness and adverse events were not obtained, we believe
that the information highlights important challenges and barriers
in the field.
Of the 51 countries identified, only Japan, Korea, Israel,
Australia, and New Zealand are considered ‘‘developed
countries’’ (UNDP, 2018). These are also the most active
countries in terms of DBS usage for both clinical practice and
research. China has had a rapid increase in surgical volume
and publications since 2009. This increase coincides with the
period when local manufacturers, including PINS and SeneRay,
produced less expensive and more accessible products. A
DBS neurostimulator (battery source) and bilateral leads have
an estimated expense of 250,000–350,000 Renminbi (RMB;
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approximately $32,000–42,000 USD). It is estimated that from
1998 to 2003, approximately 312 patients in China received DBS;
from 2003 to 2009, this number increased to approximately
1,700. Following the commercialization of products from
Chinese enterprises, over 15,000 patients have received DBS,
and over 180 hospitals now offer DBS. Finally, an increasing
number of institutions have launched DBS programs in China,
but most centers perform less than 10 cases per year and are
unclear whether proper teams and adequate quality can be
maintained at hospitals with such low volumes. In contrast, the
number of DBS cases in Japan has been decreasing over the last
few years. This might be due in part to the advent of FUS, but
more data are required to understand the underpinnings of the
recent decline.
Research on DBS in Asia has been limited. The major
barrier for DBS research has been a lack of funding from
governments and industry. Our data suggest that 77% (38) of
Asian countries have not published on DBS. In comparison,
402 DBS publications from Canada alone were revealed when
employing a similar search strategy to ours. DBS in Asia
is evolving and many barriers and challenges are remaining.
Many countries still do not have access to DBS and most
DBS publications favor East Asia and Oceania. In West
Asia, Turkey, Israel, and Iran accounted for most of the
DBS publications.
Financial cost continues to be a significant barrier to DBS
research and its widespread clinical adoption. The hardware
is expensive, the surgery is costly, and when factoring in
follow-up care these factors add up to a significant expense.
Some experts have however argued that long-term there can
be savings made from DBS (e.g., fewer medications, decreased
morbidity). Cost is problematic in the developing world, where
few citizens can afford the hardware and treatment costs. This
situation is unfortunate given the high prevalence of movement
disorders and other conditions amenable to DBS intervention.
The development of low-cost hardware may aid in ameliorating
this problem. Lower cost hardware, is, according to our data,
mostly available in China.
One issue that stood out was the lack of referrals (20/29;
69%) for DBS. This was a major impediment to DBS clinical
practice in these regions. Once referred and implanted another
interesting issue that emerged was that DBS programming
was performed by a mix of 66% neurologists and 34%
neurosurgeons. This pattern of care differs from practice patterns
in Western countries, where teams are composed mainly of
nurses and neurologists and it is rare to have neurosurgeons
programming patients. It was surprising that many Asian
centers did not have full multidisciplinary teams. The evolution
of DBS in these regions may eventually favor larger expert
centers; however, this will be addressed by a future survey.
Educational outreach is a critical unmet need across these
regions and is necessary to improve access and understanding of
DBS therapies.
Our survey has several limitations. First, we are only able
to obtain information from limited countries. We attempted
to gather information about manufacturers used in Asian
countries. However, this information is considered confidential
by some manufacturers. Similarly, the number of patients
implanted would be a better indicator of the popularization
of DBS, but some manufacturers prefer to share with us
the number of leads. Second, we selected the dates in our
search strategy based on likely capturing DBS centers with
‘‘active’’ and publications in recent years as supposed to include
all articles. We are aware that this strategy may filter out
some centers with prior DBS experience and publications
before 2013 (e.g., paper from Thailand published in 2010;
Nunta-Aree et al., 2010).
In clinical practice, microelectrode recordings remain widely
used for target refinement during surgery (94%) and the DBS
programming team consists primarily of neurologists (66%)
and neurosurgeons (34%). There was a lack of community
referrals to tertiary centers and this factor was identified as
the most common limitation for the widespread use of DBS
in Asia. In China, there has been an increasing number of
centers performing DBS surgeries. In contrast, the number
of DBS cases in Japan has been decreasing, which might be
related to the use of novel non-craniotomy approach FUS
lesioning and the availability of other advanced treatment
options. Whether this new technology has impacted DBS use
was not directly examined by our survey. Appropriate referrals,
access, infrastructure, and the lack of full multidisciplinary
DBS teams are common limitations for DBS in Asia. Most
centers in China and Japan performed less than 10 DBS
cases per year and it is unclear if low volumes will result
in suboptimal outcomes, which is a worry of experts in the
field. We know that the success of DBS relies on excellent
patient selection and the utilization of large multidisciplinary
teams. Such teams seem to be lacking in Asia and their
establishment this will be a critical next step for the field to
evolve in this region. Global educational and training programs
will be needed to scale up DBS and a focused effort will be
necessary to address financial barriers and improve the quality of
care delivery.
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